Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214468002> ?p ?o ?g. }
- W3214468002 endingPage "178" @default.
- W3214468002 startingPage "170" @default.
- W3214468002 abstract "Enzalutamide resistance has been observed in approximately 50% of patients with prostate cancer (PCa) bone metastases. Therefore, there is an urgent need to investigate the mechanisms and develop strategies to overcome resistance. We observed enzalutamide resistance in bone lesion development induced by PCa cells in mouse models. We found that the bone microenvironment was indispensable for enzalutamide resistance because enzalutamide significantly inhibited the growth of subcutaneous C4–2B tumors and the proliferation of C4–2B cells isolated from the bone lesions, and the resistance was recapitulated only when C4–2B cells were co-cultured with osteoblasts. In revealing how osteoblasts contribute to enzalutamide resistance, we found that enzalutamide decreased TGFBR2 protein expression in osteoblasts, which was supported by clinical data. This decrease was possibly through PTH1R-mediated endocytosis. We showed that PTH1R blockade rescued enzalutamide-mediated decrease in TGFBR2 levels and enzalutamide responses in C4–2B cells that were co-cultured with osteoblasts. This is the first study to reveal the contribution of the bone microenvironment to enzalutamide resistance and identify PTH1R as a feasible target to overcome the resistance in PCa bone metastases." @default.
- W3214468002 created "2021-11-22" @default.
- W3214468002 creator A5009836788 @default.
- W3214468002 creator A5019169592 @default.
- W3214468002 creator A5026553060 @default.
- W3214468002 creator A5035410669 @default.
- W3214468002 creator A5035481357 @default.
- W3214468002 creator A5038403983 @default.
- W3214468002 creator A5042151932 @default.
- W3214468002 creator A5042183327 @default.
- W3214468002 creator A5044866645 @default.
- W3214468002 creator A5046739423 @default.
- W3214468002 creator A5066609382 @default.
- W3214468002 creator A5067483347 @default.
- W3214468002 creator A5073712271 @default.
- W3214468002 creator A5083729859 @default.
- W3214468002 creator A5084513075 @default.
- W3214468002 creator A5089318076 @default.
- W3214468002 date "2022-01-01" @default.
- W3214468002 modified "2023-10-16" @default.
- W3214468002 title "Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases" @default.
- W3214468002 cites W1159619803 @default.
- W3214468002 cites W1502026371 @default.
- W3214468002 cites W1526128150 @default.
- W3214468002 cites W1655166217 @default.
- W3214468002 cites W1761343402 @default.
- W3214468002 cites W1975577875 @default.
- W3214468002 cites W1988887929 @default.
- W3214468002 cites W1990609319 @default.
- W3214468002 cites W1995194065 @default.
- W3214468002 cites W2003651863 @default.
- W3214468002 cites W2005284789 @default.
- W3214468002 cites W2007334137 @default.
- W3214468002 cites W2014751188 @default.
- W3214468002 cites W2017075573 @default.
- W3214468002 cites W2025075383 @default.
- W3214468002 cites W2031300004 @default.
- W3214468002 cites W2033178140 @default.
- W3214468002 cites W2033384572 @default.
- W3214468002 cites W2040772236 @default.
- W3214468002 cites W2044837122 @default.
- W3214468002 cites W2046964775 @default.
- W3214468002 cites W2053277543 @default.
- W3214468002 cites W2053970131 @default.
- W3214468002 cites W2063699543 @default.
- W3214468002 cites W2074202485 @default.
- W3214468002 cites W2077438659 @default.
- W3214468002 cites W2096767066 @default.
- W3214468002 cites W2113240092 @default.
- W3214468002 cites W2116708359 @default.
- W3214468002 cites W2116910749 @default.
- W3214468002 cites W2119504728 @default.
- W3214468002 cites W2124836729 @default.
- W3214468002 cites W2130189600 @default.
- W3214468002 cites W2136000914 @default.
- W3214468002 cites W2148643283 @default.
- W3214468002 cites W2151048523 @default.
- W3214468002 cites W2154256958 @default.
- W3214468002 cites W2166324735 @default.
- W3214468002 cites W2166918329 @default.
- W3214468002 cites W2171352366 @default.
- W3214468002 cites W2178058131 @default.
- W3214468002 cites W2194404144 @default.
- W3214468002 cites W2320590135 @default.
- W3214468002 cites W2328135220 @default.
- W3214468002 cites W2558217333 @default.
- W3214468002 cites W2746932121 @default.
- W3214468002 cites W2767048879 @default.
- W3214468002 cites W2770178180 @default.
- W3214468002 cites W2783974523 @default.
- W3214468002 cites W2801309958 @default.
- W3214468002 cites W2802316795 @default.
- W3214468002 cites W2897595555 @default.
- W3214468002 cites W2902784988 @default.
- W3214468002 cites W2982970399 @default.
- W3214468002 cites W3024601170 @default.
- W3214468002 cites W3127454388 @default.
- W3214468002 cites W3136531756 @default.
- W3214468002 cites W220649472 @default.
- W3214468002 doi "https://doi.org/10.1016/j.canlet.2021.10.042" @default.
- W3214468002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34752846" @default.
- W3214468002 hasPublicationYear "2022" @default.
- W3214468002 type Work @default.
- W3214468002 sameAs 3214468002 @default.
- W3214468002 citedByCount "3" @default.
- W3214468002 countsByYear W32144680022022 @default.
- W3214468002 countsByYear W32144680022023 @default.
- W3214468002 crossrefType "journal-article" @default.
- W3214468002 hasAuthorship W3214468002A5009836788 @default.
- W3214468002 hasAuthorship W3214468002A5019169592 @default.
- W3214468002 hasAuthorship W3214468002A5026553060 @default.
- W3214468002 hasAuthorship W3214468002A5035410669 @default.
- W3214468002 hasAuthorship W3214468002A5035481357 @default.
- W3214468002 hasAuthorship W3214468002A5038403983 @default.
- W3214468002 hasAuthorship W3214468002A5042151932 @default.
- W3214468002 hasAuthorship W3214468002A5042183327 @default.
- W3214468002 hasAuthorship W3214468002A5044866645 @default.
- W3214468002 hasAuthorship W3214468002A5046739423 @default.